This is our third post examining government intervention into drug pricing. If you missed either of our previous posts, you can check them out here: First post and second post. In this post, we discuss facets of modern Medicare and review relevant policy involving the...
2016 proved to be less than stellar for pharmaceutical companies for a number of reasons, not least being a low point for marketing approval of new products (22 in 2016). While the industry continues to shift the focus of R&D efforts towards compounds that carve...
Vermont recently became the first state to pass a law requiring pharmaceutical manufacturers to either disclose and explain company rationale for product price increases or face legal consequences. People within the industry naturally started to panic, as evidenced by numerous news articles. However, those who...
Every year, our bike-enthusiast team members eagerly await the national American Diabetes Association (ADA) Tour de Cure event. It’s a chance for the team to get some fresh air and exercise while helping raise money to find a cure for diabetes. Nearly 30 million people battle...